Phase 2b: icovamenib in combination with a GLP-1- based therapy in patients uncontrolled on a GLP-1-based therapy at baseline and in patients initiating a GLP-1-based therapy
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Icovamenib (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 23 Jan 2025 New trial record